Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 14/20 | 0.43 |
| ▸ | DRD2 | P14416 | 8/20 | 0.42 |
| ▸ | DRD3 | P35462 | 5/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19226640 | 0.91 | DRD4 (0.46) | DRD4DRD2DRD3CHRM2CHRM4 | |
| SCHEMBL17886515 | 0.82 | DRD4 (0.45) | DRD4DRD2DRD3CHRM2CHRM4 | |
| SCHEMBL21214301 | 0.80 | DRD4 (0.44) | DRD4DRD2DRD3CHRM2CHRM4 | |
| SCHEMBL7833509 | 0.77 | DRD2 (0.59) | DRD4DRD2DRD3ADRA1DADRA1A | |
| SCHEMBL10819399 | 0.76 | DRD4 (0.54) | DRD4DRD2DRD3CHRM2CHRM4 | |
| SCHEMBL171599 | 0.74 | DRD4 (0.48) | DRD4DRD2DRD3CHRM2CHRM4 | |
| SCHEMBL29352448 | 0.74 | DRD4 (0.48) | DRD4DRD2DRD3CHRM2CHRM4 | |
| SCHEMBL7225762 | 0.73 | DRD4 (0.45) | DRD4DRD2DRD3CHRM2CHRM4 | |
| SCHEMBL7215923 | 0.73 | RAB9A (0.49) | DRD4DRD2DRD3GRM2 | |
| SCHEMBL19117549 | 0.72 | DRD4 (0.50) | DRD4DRD2DRD3ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | DRD4 4544/4885DRD2 4124/4885DRD3 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.